Skip to Main Content

As a World Health Assembly meeting nears, several European countries are proposing numerous changes that patient advocates argue would water down a resolution designed to create more transparency around prescription drug pricing.

At a planning session earlier this week, nearly a dozen countries — particularly Germany, Denmark, the U.K., and Sweden — offered a bevy of subtle and not-so-subtle suggestions for softening language used to describe pricing as well as for disclosing R&D costs, patent holdings, and clinical trial results, among other things. A final version, which must still be crafted, will be vetted at the WHA meeting that starts on May 20 in Geneva.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • And, this change was pretty big.

    Opt 1.3 [Require as a condition of registration for medicines, vaccines cell
    and gene-based therapies and other relevant technologies;

    a) Annual Reports on sales revenues, prices and units sold,

    b) Annual Reports on marketing costs incurred for each registered product
    or procedure,

    c) The R&D costs directly associated with each clinical trial used to support
    the registration of a product or procedure, separately, and

    d) All grants, tax credits or any other public sector subsidies and incentives
    relating to the initial regulatory approval and annually on the subsequent
    development of a product or procedure; (DEL USA, Australia, Denmark)]

Comments are closed.